Tuesday, August 23, 2016
BioPharma Services USA has been awarded a five-year, $20 million contract with the Center for Drug Evaluation and Research (CDER), a division of the FDA. The contract is to conduct in vivo studies of generic drug products in human subjects over a period of five years, from 2016 through to 2021.
BioPharma Services (BPSI) has entered into a partnership and joint venture agreement with Scentryphar, a CRO located in Sao Paulo, Brazil. The partnership will support local and global sponsors looking to bring generic and innovative drugs to the Brazilian market by offering one-stop shopping and joint experience in clinical conduct, bioanalysis, data management, statistics and scientific and medical writing.